

Non-natural Elemene as the “Stepping Stone” for the Synthesis of Germacrane and Guaiane Sesquiterpenes


Elissavet E. Anagnostaki and Alexandros L. Zografos*

Department of Chemistry, Laboratory of Organic Chemistry, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece

alzograf@chem.auth.gr

Received November 20, 2012

ABSTRACT



The synthesis of hydroxyelemene 5 from (*R*)-carvone and its utilization as a common synthetic scaffold to produce structurally diverse germacrane and guaiane sesquiterpenes are described. A highly enantio- and stereoselective biomimetic tandem oxy-Cope/ene rearrangement was used as the key reaction to access the 10-membered macrocyclic core of germacrane and the condensed 5–7 carbocycles of guaiane sesquiterpenes. Additionally, reactions of furanoguaianes under acidic or oxidizing reagents have been investigated, and preliminary results of these conversions are presented.

Sesquiterpenes are plant-derived compounds often used in traditional medicine¹ against inflammation and cancer.² Comprising more than 5000 members,³ sesquiterpene subfamilies provide an infinite synthetic challenge for organic chemists because of their complex molecular diversity⁴ and rich biological profile.⁵ Sesquiterpenoid-derived drugs from thapsigargin (1),⁶ parthenolide (2),⁷

and artemisinin (3)⁸ (Figure 1) are now in clinical trials for an array of tumor cell lines. More specifically, parthenolide (2), a 6,12-germacranolide, was found to selectively reduce the growth of tumor cells⁷ by its potent ability to inhibit an NF- κ B signaling pathway.² Yet, despite the promising array of biochemical behavior, the true clinical potential for these compounds and especially their isomeric 8,12-sesquiterpene analogues has barely been tapped. Taxonomically,

- (1) Merfort, I. *Curr. Drug Targets* **2011**, *12*, 1560–1573.
- (2) Hehner, S. P.; Heinrich, M.; Bork, P. M.; Vogt, M.; Ratter, F.; Lehmann, V.; Schulze-Osthoff, K.; Dröge, W.; Lienhard Schmitz, M. *J. Biol. Chem.* **1998**, *273*, 1288–1297.
- (3) Schmidt, T. J. *Stud. Nat. Prod. Chem.* **2006**, *33*, 309–392.
- (4) Series of Annual Reviews by: Fraga, B. M. *Nat. Prod. Rep.* **2011**, *28*, 1580–1610.
- (5) (a) Ghantous, A.; Gali-Muhtasib, H.; Vuorela, H.; Saliba, N. A.; Darwiche, N. *Drug Discov. Today* **2010**, *15*, 668–678. (b) Picman, A. K. *Biochem. Syst. Ecol.* **1986**, *14*, 255–281.
- (6) Christensen, S. B.; Skytte, D. M.; Denmeade, S. R.; Dionne, C.; Moller, J. V.; Nissen, P.; Isaacs, J. T. *Anticancer Agents Med. Chem.* **2009**, *9*, 276–294.
- (7) Pajak, B.; Orzechowski, A.; Gajkowska, B. *Folia Histochem. Cytobiol.* **2008**, *46*, 129–135.

- (8) Efferth, T. *Curr. Drug Targets* **2006**, *7*, 407–421.
- (9) (a) Shibuya, H.; Ohashi, K.; Kawashima, K.; Hori, K.; Murakami, N.; Kitagawa, I. *Chem. Lett.* **1986**, 85–86. (b) Takahashi, T.; Nemoto, H.; Kanda, Y.; Tsuji, J.; Fukazawa, Y.; Okajima, T.; Fujise, Y. *Tetrahedron* **1987**, *43*, 5499–5520.
- (10) (a) Schall, A.; Reiser, O. *Eur. J. Org. Chem.* **2008**, 2353–2364. (b) Andrews, S. P.; Ball, M.; Wierschem, F.; Cleator, E.; Oliver, S.; Hogenauer, K.; Simic, O.; Antonello, A.; Hunger, U.; Smith, M. D.; Ley, S. V. *Chem.—Eur. J.* **2007**, *13*, 5688–5712. (c) Sun, L.; Shah, F.; Helal, M. A.; Wu, Y.; Pedduri, Y.; Chittiboyina, A. G.; Gut, J.; Rosenthal, P. J.; Avery, M. A. *J. Med. Chem.* **2010**, *53*, 7864–7868. (d) Yang, H.; Qiao, X.; Li, F.; Ma, H.; Xie, L.; Xu, X. *Tetrahedron Lett.* **2009**, *50*, 1110–1112. (e) Lee, E.; Lim, J. W.; Yoon, C. H.; Sung, Y. S.; Kim, Y. K.; Yun, M.; Kim, S. *J. Am. Chem. Soc.* **1997**, *119*, 8391–8392.

8,12-members represent half of the components isolated from Nature. Although numerous synthetic strategies exist in order to access the carbocyclic cores of 6,12-germacranolides⁹ and 6,12-guaianolides,¹⁰ rather few references appear in the literature for the synthesis of isomeric 8,12-germacranolides and 8,12-guaianolides,¹¹ and even fewer study their biological profile.




Figure 1. (A) Biosynthetic correlation of sesquiterpenoids and (B) selected examples of biological active sesquiterpenoids.

Intrigued by the structural infinity and the possible biological activity of these sesquiterpenes, our group initiated a research effort to discover a novel and efficient synthetic route to 8,12-sesquiterpene motifs. The rich diversity of this class is well delineated by the existence of germacrane, guaiane, pseudoguaiane, elemene, eudesmane, and lindene subfamilies (Figure 1).⁴ In a hypothetical carbocyclic sesquiterpene biosynthetic pyramid, germacrane lay on top accounting for all the presented diversity. However, the exact nature and sequence of these biosynthetic steps are currently unknown, and their investigation remains a challenging task.¹² On the basis of this biosynthetic hypothesis, furanogermenone (**4**)¹³ was envisioned as an ideal common synthetic scaffold to access the rich diversity of the 8,12-subfamily. Retrosynthesis of **4** was designed through an irreversible oxy-Cope rearrangement of the non-natural elemene compound **5**, avoiding the known equilibration between germacrane and elemene pair which predominantly produces the elemene component.¹⁴ Elemene **5** could then be disconnected to carveol **8** utilizing an array of sequential oxidation and alkyl addition steps (Figure 2).

(11) (a) Tanis, S. P.; Robinson, E. D.; McMills, M. C.; Watt, W. *J. Am. Chem. Soc.* **1992**, *114*, 8349–8362. (b) Valot, G.; Garcia, J.; Duplan, V.; Serba, C.; Barluenga, S.; Winssinger, N. *Angew. Chem., Int. Ed.* **2012**, *51*, 5391–5394.

(12) Miller, D. J.; Allemann, R. K. *Nat. Prod. Rep.* **2012**, *29*, 60–71.

(13) Shibuya, H.; Yamamoto, Y.; Miura, I.; Kitagawa, I. *Heterocycles* **1982**, *17*, 215–218.

(14) (a) Jain, T. C.; Banks, C. M.; McCloskey, J. E. *Tetrahedron Lett.* **1970**, *11*, 841–844. (b) Rosselli, S.; Maggio, A.; Raccuglia, R. A.; Bruno, M. *Eur. J. Org. Chem.* **2003**, 2690–2694.




Figure 2. Initial retrosynthetic plan for the synthesis of furanogermenone (**4**).

Despite the direct accessibility to the *syn*-carveol **8**,¹⁵ its oxidation to the ketone **7** was perceived to be rather problematic. Thus, when it was allowed to be oxidized under a number of reported conditions (chromium pyrazole,¹⁶ TEMPO,¹⁷ PCC,¹⁸ PDC,^{18b} *t*-BuOOH in the presence of metals,¹⁹ etc.), an inconsistent, inseparable mixture of oxidized products was observed in very low yields (5–12%). After extended experimentation, it was found that when *anti*-carveol **10**²⁰ was used instead of **8** in reaction under singlet oxygen conditions,²¹ a 2:1 diastereoisomeric mixture of α - and β -hydroxylated products was obtained, which after selective protection of secondary alcohols with pivaloyl group and chromatographic purification led to the desired compound **11** in 39% overall yield (Scheme 1). Hydroxyl migration of the unprotected tertiary alcohol followed by direct oxidation with PCC²² afforded the α,β -unsaturated ketone **12**. 1,4-Conjugated addition of vinyl group, promoted by copper iodide,²³ produced the alkylated product **13** in high diastereoselectivity (ratio 12:1) favoring the *syn*-orientation between the methyl and the

(15) Garver, L.; Van Eikeren, P. *J. Org. Chem.* **1976**, *41*, 2273–2274.

(16) Sakagami, M.; Muratake, H.; Natsume, M. *Chem. Pharm. Bull.* **1994**, *42*, 1393–1398.

(17) (a) Shibuya, M.; Tomizawa, M.; Iwabuchi, Y. *Org. Lett.* **2008**, *10*, 4715–4718. (b) Vatele, J.-M. *Tetrahedron* **2010**, *66*, 904–912.

(18) (a) Kuroda, C.; Nakamura, T.; Hirota, H.; Enomoto, K.; Takahashi, T. *Bull. Chem. Soc. Jpn.* **1985**, *58*, 146–151. (b) Fouteris, M. A.; Koutsourea, A. I.; Nikolaropoulos, S. S.; Riah, A.; Muzart, J. *J. Mol. Catal. A-Chem.* **2006**, *250*, 70–74. (c) Dauben, W. G.; Lorber, M.; Fullerton, D. S. *J. Org. Chem.* **1969**, *34*, 3587–3592. (d) Nakayama, M.; Shinke, S.; Matsushita, Y.; Ohira, S.; Hayashi, S. *Bull. Chem. Soc. Jpn.* **1979**, *52*, 184–185.

(19) (a) Zhao, Y.; Yueng, Y.-Y. *Org. Lett.* **2010**, *12*, 2128–2131. (b) Catir, M.; Kilic, H. *Synlett* **2010**, 9, 1319–1322. (c) Yang, M.; Peng, Q.-R.; Lan, J.-B.; Song, G.-F.; Xie, R.-G. *Synlett* **2006**, 2617–2620. (d) Salvador, J. A. R.; Silvestre, S. M. *Tetrahedron Lett.* **2005**, *46*, 2581–2584. (e) Miller, A. R.; Li, W.; Hymphrey, R. G. *Tetrahedron Lett.* **1996**, *37*, 3429–3432. (f) Shing, T. K. M.; Yeung, Y.; Su, P. L. *Org. Lett.* **2006**, *8*, 3149–3151.

(20) (a) Salvador, J. A. R.; Leitão, A. J.; L. Sa e Melo, L.; Hanson, J. R. *Tetrahedron Lett.* **2005**, *46*, 1067–1070. (b) The enantiomeric excess of compound **10** was calculated to be 72%. This material was chirally resolved to 93% ee.

(21) Alberti, M. N.; Orfanopoulos, M. *Synlett* **2010**, 999–1026.

(22) Fernández-Mateos, A.; Ramos Silvo, A. I. R.; Rubio González, R.; Simmonds, M. S. J. *Tetrahedron* **2006**, *62*, 7809–7816.

(23) Lipshutz, B. H. Organocopper Chemistry. In *Organometallics in Synthesis: A Manual*, 2nd ed.; Schlosser, M., Eds.; Wiley & Sons Ltd.: West Sussex, 2002; p 762.

9 $\xrightarrow{\text{ref 20}}$ **10** $\xrightarrow{\begin{smallmatrix} 1. \text{O}_3, \text{hv} \\ \text{MB, CH}_3\text{CN} \\ 2. \text{DMS, DCM} \\ 3. \text{PivCl} \\ \text{Et}_3\text{N, DCM} \end{smallmatrix}}$ **11** (39% from **10**)

11 $\xrightarrow{\begin{smallmatrix} \text{PCC} \\ \text{DCM} \end{smallmatrix}}$ **12** (58%)

12 $\xrightarrow{\begin{smallmatrix} \text{MgBr} \\ \text{Cul, Et}_2\text{O} \end{smallmatrix}}$ **13** (78%)

13 $\xrightarrow{\begin{smallmatrix} 1. \text{mCPBA, DCM} \\ 2. \text{KOH, MeOH} \end{smallmatrix}}$ **14** (82%)

14 $\xrightarrow{\begin{smallmatrix} 1. \text{K}_2\text{CO}_3, \text{MeOH} \\ 2. \text{DMP, DCM} \end{smallmatrix}}$ **15** (70%)

15 $\xrightarrow{\begin{smallmatrix} \text{Br} \\ \text{t-BuLi, Et}_2\text{O} \end{smallmatrix}}$ **5** (70%)

5 $\xrightarrow{\begin{smallmatrix} 120^\circ\text{C} \\ 7 \text{ h, toluene} \end{smallmatrix}}$ **4** (42%)

4 $\xrightarrow{\begin{smallmatrix} 1. \text{O}_3, \text{hv} \\ \text{MB} \end{smallmatrix}}$ **16**

16 $\xrightarrow{\begin{smallmatrix} \text{DMS} \\ \text{DCM} \end{smallmatrix}}$ **17** (19%)

4 Furanogermene **4**

17 Methyl-Curdionolide **17**

16


(24) Fuchs, S.; Zinn, S.; Beck, T.; Mosandl, Á. *J. Agric. Food Chem.* **1999**, *47*, 4100–4105.

(26) Yick, C.-Y.; Wong, H. N. C. *Tetrahedron* **2001**, *57*, 6935–6940.

(28) The enantiomeric excess was calculated based on the optical

(29) Lou, Y.; Zhao, F.; Wu, Z.; Peng, K.-F.; Wei, X.-C.; Chen, L.-X.; Qiu, F. *Helv. Chim. Acta* **2009**, 92, 1665–1672.

Inspired by the elegant work of Barriault and his group on tandem oxy-Cope/ene reactions,³⁰ we aimed to explore the ability of elemene **5** to serve as a common synthetic scaffold to the synthesis of diverse guaiane structures. Thus, when **5** was heated to the higher temperature of 140 °C for prolonged reaction times the same products **20** and **22** were observed in 40% and 8% yields, respectively.



Specifically, heating compound **5** rearranges the six-membered ring to the 10-membered enol carbocycle **18**. The macrocycle exists exclusively in conformation **18** due to the energetically demanding rotation of tetrasubstituted enol moiety inside the macrocycle (Figure 3).²⁷ Selective protonation from the least hindered face of **18** delivers **4A** in high enantioselectivity compared to the starting carveol **10**. The initially formed conformer **4A** directs the methyl group axially, leading to disfavored 1,3- and 1,5-diaxial interactions. In order for the ene reaction to proceed, the

(30) For excellent studies on the topic: (a) Sauer, E. L. O.; Barriault, L. *J. Am. Chem. Soc.* **2004**, *126*, 8569–8575. (b) Barriault, L.; Deon, D. H. *Org. Lett.* **2001**, *3*, 1925–1927. (c) Arns, S.; Lebrun, M.-E.; Grisé, C. M.; Denissova, I.; Barriault, L. *J. Org. Chem.* **2007**, *72*, 9314–9322. (d) Arns, S.; Barriault, L. *Chem. Commun.* **2007**, 2211–2221. (e) Hooper, J.; Sauer, E. L. O.; Arns, S.; Woo, T. K.; Barriault, L. *Chem.–Eur. J.* **2010**, *16*, 14124–14130.

The reaction scheme illustrates the synthesis of compound 5 from compound 4. Compound 4 is a bicyclic molecule with a furan ring and a methyl group. It is converted to compound 22 (8% yield) or compound 20 (58% yield from 4, 40% from 5) via an *ene*-reaction at 140 °C for 12 hours. Compound 20 is then converted to compound 5 (140 °C, 12 h) via a tandem oxy-Cope/*ene*-reaction using TFA in DCM (98% yield). Compound 5 is a bicyclic molecule with a furan ring and a methyl group. Compound 22 is converted to compound 25 (99% yield) via an air oxidation over 2 days. Compound 25 is a bicyclic molecule with a furan ring and a methyl group. The mechanism for the conversion of 22 to 25 involves the formation of a radical intermediate (23) and a peroxide intermediate (24), which then rearranges to form 25.

Furanogualane **20** was also found to be extremely sensitive upon standing. Thus, leaving a sample of **20** in deuteriurated chloroform for 2 days at 5 °C led to the selective formation of lactole product **25** through its

In conclusion, there is a high demand for reaction sequences that lead to diverse structures of biologically interesting scaffolds. The present study illustrates a highly efficient route to the synthesis of divergent germacrane, guaiane and furomelampolide natural core structures emerging from the different cyclization modes of the common non-natural elemene scaffold **5**. The syntheses of the three distinct classes of sesquiterpenes described above have been evolved relying either on the development of a highly enantioselective oxy-Cope reaction for the construction of germacrane or its advancement to the complete diastereoselective oxy-Cope/ene reaction cascade to access guaiane structural motifs. Reactions that direct guaiane **20** either to furomelampolide **21** through an acidic retro-ene reaction or to the congested **25** by its spontaneous oxidation have also been explored shedding light upon potential existing biosynthetic transformations. The common non-natural elemene scaffold **5** is expected to be proven applicable in the synthesis of other diverge members of the sesquiterpene family such as lindenanes, eudesmanes, pseudoguaianes, etc., providing a reliable entry to prevalidated libraries of sesquiterpenoids. Further studies on these directions are currently in progress and will be communicated in due course.

Supporting Information Available. Experimental procedures and characterization data for all compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>

Org. Lett., Vol. 15, No. 1, 2013